SYSTEMATIC REVIEW

REVISED Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies [version 3; peer review: 1 approved, 1 approved with reservations]

Fausto Petrelli¹ , Antonio Ghidini², Michele Ghidini³, Roberta Bukovec², Francesca Trevisan⁴, Luca Turati⁵, Alice Indini³, Silvia Seghezzi⁶, Veronica Lonati¹, Giovanna Moleri⁷, Gianluca Tomasello³, Alberto Zaniboni⁸

¹Oncology Unit, asst bergamo ovest, Treviglio (BG), Italy

²Oncology Unit, casa di cura igea, Milan, Italy

³Oncology Unit, IRCCS Foundation Ospedale Maggiore Policlinico, Milan, Italy

⁴Radiotherapy Unit, Poliambulanza Institute Foundation Hospital, Treviglio (BG), Italy

⁵Surgery Unit, ASST Bergamo ovest, Treviglio (BG), Italy

⁶Nuclear Medicine Unit, ASST Bergamo ovest, Treviglio (BG), Italy

⁷Direzione socio sanitaria, Centro servizi, ASST Bergamo ovest, Treviglio (BG), Italy

⁸Oncology Unit, Fondazione Poliambulanza, Brescia, Italy

V3 First published: 27 May 2021, 10:423
<https://doi.org/10.12688/f1000research.52546.1>

Second version: 25 Aug 2021, 10:423
<https://doi.org/10.12688/f1000research.52546.2>

Third version: 15 Nov 2021, 10:423
<https://doi.org/10.12688/f1000research.52546.3>

Latest published: 12 May 2022, 10:423
<https://doi.org/10.12688/f1000research.52546.4>

Abstract

Background: The modern concept of oligometastatic (OM) state has been initially developed to describe patients with a low burden of disease and with a potential for cure with local ablative treatments. We systematically assessed the risk of death and relapse of oligometastatic (OM) cancers compared to cancers with more diffuse metastatic spread, through a meta-analysis of published data.

Methods: PubMed, the Cochrane Library, and EMBASE were searched for studies reporting prognosis of patients with OM solid tumors. Risk of death and relapse were extracted and pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI). The primary outcome of the study refers to overall mortality in OM vs. polymetastatic (PM) patients.

Results. Mortality and relapse associated with OM state in patients with cancer were evaluated among 104,234 participants (n=173 studies). Progression-free survival was better in patients with OM disease (hazard ratio [HR] = 0.62, 95% CI 0.57–0.68; P <.001; n=69

Open Peer Review

Approval Status

	1	2
version 4		
(revision)		
12 May 2022		
version 3		
(revision)		
15 Nov 2021		
version 2		
(revision)		
25 Aug 2021		
version 1		
27 May 2021		

1. Luca G. Campana , The Christie NHS Foundation Trust, Manchester, UK

studies). Also, OM cancers were associated with a better overall survival (OS) (HR = 0.65, 95% CI 0.62-0.68; $P < .01$; $n = 161$ studies). In colorectal (CRC), breast, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) the reduction in the risk of death for OM patients were 35, 38, 30 and 42%, respectively. Biliary tract and cervical cancer do not significantly better in OM stage likely for paucity of data.

Conclusions. Patients with OM cancers have a significantly better prognosis than those with more widespread stage IV tumors. In OM cancer patients a personalized approach should be pursued.

Keywords

cancer, oligometastases, survival, review, meta-analysis, tumours

Manchester University NHS Foundation Trust,
Manchester, UK

2. **Dario Baratti**, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy

Any reports and responses or comments on the
article can be found at the end of the article.

This article is included in the **Oncology**
gateway.

Corresponding author: Fausto Petrelli (faupe@libero.it)

Author roles: **Petrelli F:** Conceptualization, Data Curation, Formal Analysis, Methodology, Resources, Software, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Ghidini A:** Data Curation, Writing – Original Draft Preparation; **Ghidini M:** Supervision, Validation, Writing – Original Draft Preparation; **Bukovec R:** Data Curation, Writing – Original Draft Preparation; **Trevisan F:** Formal Analysis, Supervision, Validation, Writing – Original Draft Preparation; **Turati L:** Validation, Visualization, Writing – Original Draft Preparation; **Indini A:** Validation, Visualization, Writing – Original Draft Preparation; **Seghezzi S:** Supervision, Validation, Visualization, Writing – Original Draft Preparation; **Lonati V:** Data Curation, Formal Analysis, Methodology, Software, Writing – Original Draft Preparation; **Moleri G:** Data Curation, Formal Analysis, Funding Acquisition, Methodology, Project Administration, Writing – Original Draft Preparation; **Tomasello G:** Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Zaniboni A:** Conceptualization, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Petrelli F *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Petrelli F, Ghidini A, Ghidini M *et al.* **Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies [version 3; peer review: 1 approved, 1 approved with reservations]** F1000Research 2021, 10:423 <https://doi.org/10.12688/f1000research.52546.3>

First published: 27 May 2021, 10:423 <https://doi.org/10.12688/f1000research.52546.1>

REVISED Amendments from Version 2

We have provided new figure 3 explaining and graphically define the difference in subgroup analysis according to primary tumor. We provided a brief discussion about site of oligometastases in discussion section as requested.

Any further responses from the reviewers can be found at the end of the article

Introduction

The vast majority of metastatic solid tumors are incurable, and despite the evolution of treatments, patients ultimately die because of their disease. The modern concept of oligometastatic (OM) state was initially developed in 1995¹ to describe patients with a low burden of disease (e.g. 1 to 3-5 metastases) with a potential for cure with local ablative treatments. This assumption also relies on the hypothesis that metastatic spread follows a hierarchical pattern in time and number of localizations.² In some circumstances, the 8th Tumor Node Metastasis (TNM) staging system distinguishes between patients with a single metastasis and those with multiple such metastases. Large consensus on the definition and management of OM patients is currently lacking. Clinically, those cancers with a lower burden of metastatic disease have a favorable prognosis and they may be amenable of local treatment for the primary and distant tumors. Recently, in fact, advances in imaging and local ablative therapies have permitted the treatment of these patients with additional locoregional treatment in addition to systemic therapies, and some patients may be cured and attain long term survival.³ This scenario has been best elucidated in genitourinary, lung and melanomas.^{4,5} In these settings oligometastatic cancers may be treated in oligoprogressive sites continuing systemic therapy that control the remaining disease. One of the first published trials proving benefit of an aggressive local treatment of oligometastases was published in Lancet during 2019. In the SABR-COMET randomized study median overall survival (OS) was 28 months (95% CI 19-33) in the control group versus 41 months (26-not reached) in the stereotactic body radiotherapy to all metastases group (hazard ratio 0.57, 95% CI 0.30-1.10; P = .09).⁶

The aim of this systematic review and meta-analysis was to investigate and establish the prognostic survival of OM compared to non-OM solid tumors. In particular, we evaluated if patients with oligometastatic solid tumors do better than patients with non-oligometastatic tumors defined as tumors with up to three to five metastatic sites.

Methods

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Search strategy and inclusion criteria

A comprehensive search was performed with the following terms: (*advanced or metastatic or recurrent or relapsed or synchronous or metachronous*) and (*site or oligo* or "oligometastatic" or oligorecurrence or oligoprogression or single or multiple or 1-3 or >3 or >4 or >5 or 1-2 or 1-3 or 1-5 or number*) and (*synchronous or metachronous or metastases or relapse or recurrence or progression*) and (*tumor or tumour or cancer or carcinoma or melanoma or sarcoma*) and (*"hazard ratio"*) and (*cox or multivariate or multivariable*) and *survival*. We searched PubMed, the Cochrane Library and EMBASE for studies eligible for this meta-analysis published in English language from inception up to October 30th, 2020. To be eligible, studies needed to have evaluated survival of patients with OM cancers (1 up to 3/5 metastases regardless of anatomic sites) regardless of line of therapy and to provide data of outcome according to the number of OM sites used by each author. Studies were excluded if they enrolled less than 10 patients, pediatric subjects, and hematological diseases. Commonly we define polymetastatic cancer as any disease with more than three to five metastases. Studies were searched and screened independently by three authors (FP, MG and GT).

Quality of studies and endpoints

The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for observational or retrospective studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). With NOS scale, studies were defined as poor, sufficient or good quality if scores (the sum of points attributed to each domain) were <6, 6 or 7-9 points, respectively.

Data extraction and statistical analysis

The extracted data (from six reviewers) included the type of study, number of patients, cancer type, median age of included patients, performance status 0-1 (rate), treatment received, timing of oligometastases (synchronous or meta-chronous), number of OM sites used for comparison, and median follow up. Hazard ratios (HR) for OS and PFS with their 95% CIs, were extracted preferentially from multivariate analyses where available. The heterogeneity in the included

studies was evaluated by the Chi-square-based Q-test and I^2 ($I^2 = 0\%$ to 25% , no heterogeneity; $I^2 = 25\%$ to 50% , moderate heterogeneity; $I^2 = 50\%$ to 75% , high heterogeneity; $I^2 = 75\%$ to 100% , extreme heterogeneity). When I^2 was larger than 50% , a random effects model was used; otherwise, the fixed effects model was used. Sensitivity analyses for OS were performed according to type of cancer, timing and number of oligometastases to find the potential heterogeneity among the included studies. If the number of studies was less than or equal to one, we did not carry out the subgroup analysis. The possibility of publication bias was explored by the Egger's and Begg's tests and Trim and Fill method.^{7,8} Begg's test explores bias with a funnel plot, conversely Egger's test is a linear regression of the effect estimates (OS) on their standard errors weighted by their inverse variance. The trim-and-fill method aims at estimating potentially missing studies due to publication bias in the funnel plot and adjusting the overall effect estimate. All analyses were performed using RevMan v.3 software.⁹

Results

Among the publications retrieved using electronic search ($n = 7510$), 173 studies were eligible for meta-analysis, for a total of 104,234 patients¹⁰ (Figure 1). Baseline characteristics of the included studies and treatments received are presented in Table 1.

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 flow diagram showing the process of study inclusion.

Table 1. Characteristics of included studies.

Author/year	N° pts	Disease	Median age (years)/PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Morino/2020	232	Biliary	66/NR	Retrospective	12.6	1-3 (52)	Various	-	± Locoregional ± Systemic tx	UVA	-	5
Park/2017	134	Biliary	61/90	Retrospective	26	0-1 (90)	Various	-	CT (100)	MVA	MVA	6
Luzzago/2019	1592	Bladder	68/NR	Retrospective	NR	1 (44)	Various	-	CT ± S	MVA	-	5
Bates/2011	96	Breast	NR/NR	Retrospective	NR	1-2 (NR)	Various	-	CT (100)	MVA	MVA (TTP)	5
Blanchette/2018	154	Breast	56/NR	Retrospective	34	1 (55)	Various	25/75	CT (100)	MVA	-	7
Buhl/2018	140	Breast	62/NR	Retrospective	6.2	1 (40)	Various	-	CT (100)	-	MVA (TTP)	5
Co/2019	172	Breast	53/NR	Retrospective	NR	1-3 (96)	Various	100/0	Systemic tx ± S (100)	MVA	-	5
Gobbini/2018	16702	Breast	61/NR	Cohort	48.5	1-3 (92.6)	Various	28.5/71.5	-	MVA	-	8
Gu/2020	1888	Breast	NR/NR	Retrospective	NR	1 (NR)	Various	100/0	Various	MVA	-	5
Ivars Rubio/2019	263	Breast	59/81.4	Retrospective	44.9	1 (57.8)	Various	44.5/55.5	OT (19.8) CT (50.7) CT + Bio (29.5)	UVA	UVA	7
Kikawa/2019	134	Breast	63.5/85.8	Retrospective	NR	1-2 (73.9)	Various	24.6/75.4	Everolimus (100)	UVA	UVA	5
Kroger/2006	187	Breast	45.5/NR	Phase 3	63	1-2 (41.5)	Various	29.5/70.5	CT (100)	MVA	MVA	7
Le Scodan/2009	581	Breast	60.2/NR	Retrospective	39	1 (58.9)	Various	100/0	RT ± S	MVA	-	7
Leone/2017	9143	Breast	61/NR	Retrospective	13	1 (36.2)	Various	100/0	-	MVA	-	6
Lipton/2010	102	Breast	55.4/100	Retrospective	34	1-2 (NR)	Various	-	Trastuzumab (100) ± CT (88)	MVA	MVA (TTP)	6
Lobbezoo/2015	815	Breast	62.5/NR	Retrospective	37.1	1 (67)	Various	19/81	Systemic tx (100)	MVA	-	6
Neuman/2010	186	Breast	56/NR	Retrospective	52	1 (13)	Various	100/0	CT (100)	MVA	-	8
Nguyen/2012	692	Breast	60/68.9	Retrospective	22.8	1-4 (33.6)	Various	-	± Locoregional ± Systemic tx	MVA	-	6
Niikura/2012	314	Breast	51.9/90.4	Retrospective	33	1 (23.8)	Bone	100/0	Bisphosphonates	MVA	MVA	6
Park/2009	317	Breast	48/93	Retrospective	NR	1-2 (36)	Various	-	Various	MVA	-	5

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Pons-Tostvint/2019	4276	Breast	60/NR	Retrospective	45.3	1-2 (77)	Various	100/0	Various	MVA	-	7
Ran/2020	49	Breast	50/NR	Retrospective	29	1-2 (NR)	Various	-	Trastuzumab based (100)	UVA	-	6
Rhu/2014	262	Breast	47/NR	Retrospective	29.6	1-2 (84.7)	Various	100/0	Various	MVA	-	6
Schneeweiss/2002	118	Breast	44/NR	Retrospective	48	1-2 (86)	Various	-	CT (100)	UVA	MVA	7
Wong/2019	483	Breast	49/NR	retrospective	66	1 (88)	Various	100/0	Systemic tx (100)	MVA	-	7
Smart/2019	66	BTC	76/55	Retrospective	21	1-2 (54)	Liver	-	RT (100)	MVA	MVA	6
Yin/2019	99	Cervix	53/51.6	Retrospective	11.6	1-3 (37.3)	Various	-	-	MVA	MVA	6
Afshari/2019	281	CRC	62/NR	Retrospective	NR	1 (85)	Various	-	-	MVA	-	5
Amikura/2017	342	CRC	NR/NR	Retrospective	52.7	1-4 (75.7)	Liver	63/37	S ± CT (100)	MVA	MVA	8
Aparicio/2016	282	CRC	80/100	Phase 3	69.8	1-2 (77.8)	Various	-	CT (100)	MVA	MVA	-
Araujo/2015	318	CRC	58/NR	Retrospective	60	1 (43)	Liver	-	S (100) + CT (37)	-	MVA	8
Bachet/2019	249	CRC	62.9/NR	Retrospective	28.7	1-3 (66)	Liver	79/21	S ± CT (100)	UVA	MVA (DFS)	6
Baldin/2021	221	CRC	62/NR	Retrospective	44.5	1-3 (75.6)	Liver	74.2/25.8	S ± perioperative tx (100)	MVA	MVA (TTR)	7
Beppu/2014	137	CRC	63/NR	Retrospective	NR	1-5 (NR)	Liver	-	CT ± S (100)	MVA	-	5
Blazer III/2008	305	CRC	57/NR	Retrospective	25	1 (32)	Liver	-	CT + S (100)	MVA	-	6
Brandl/2013	151	CRC	61.5/100	Retrospective	42	1 (61)	Lung / Liver	51/49	S ± CT (100)	-	MVA	8
Cardona/2013	1004	CRC	NR/NR	Retrospective	59	1 (42)	Liver	-	S (100)	MVA	-	8
Catalano/2009	255	CRC	67/92	Retrospective	45	1 (64)	Various	0/100	CT (100)	MVA	-	8
Chen/2010	255	CRC	NR/NR	Retrospective	11.9	1 (67)	Various	100/0	CT (67)	MVA	-	6
Comella/2005	254	CRC	NR/97	Pooled analysis of n=2 trials	NR	1 (55)	Various	54/46	CT (100)	MVA	MVA	5
Creasy 2018	907	CRC	64/NR	Retrospective	122	1 (52.7)	Liver	-	S + CT (100)	MVA	MVA	8

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Cristobal/2014	250	CRC	69.5/81	Retrospective	NR	1-2 (90)	Various	65/35	NR	UVA	MVA	5
Daniel/2017	109	CRC	58.4/NR	Retrospective	NR	1-4 (46)	Liver	100/0	S ± CT (100)	MVA	-	5
de Geus-Oei/2006	152	CRC	61.5/NR	Prospective	17	1 (NR)	Liver	-	Various	UVA	UVA	6
Efficace/2008	742	CRC	62/92	Retrospective analysis	NR	1 (40)	Various	-	CT (100)	MVA	-	5
Faron/2015	810	CRC	63/83	Pooled analysis of n=4 trials	33	1-2 (85)	Various	100/0	CT ± S	MVA	MVA	6
Ghiringhelli/2014	409	CRC	65/59	Retrospective	32	1 (63)	Various	62/38	S ± CT (100)	MVA	-	6
Gu/2018	102	CRC	62/NR	Retrospective	NR	1 (36)	Liver	0/100	RFA ± CT (100)	MVA	-	5
Hebbbar/2015	284	CRC	61.7/93	Phase 3	67	1 (48.9)	Various / Liver 83.5	67.7/32.3	S + CT (100)	-	MVA (DFS)	8
Hernandez/2016	522	CRC	64.5/NR	Retrospective	38.7	1 (65.7)	Lung	-	CT	MVA	MVA	6
Holliday/2017	34	CRC	56/NR	Retrospective	25	1-2 (100)	Various	100/0	SCRT	MVA	MVA	6
Huang/2020	179	CRC	62/NR	Retrospective	27.6	1 (51.5)	Lung	-	S (100)	MVA	-	6
Ishiguro/2006	111	CRC	NR/NR	Retrospective	43	1-3 (81)	Liver	100/0	S (100)	MVA	-	9
Kemeny/2014	169	CRC	55/NR	Retrospective	44.3	1-2 (47.3)	Various	66.8/33.2	S + HAI + Systemic tx (100)	-	MVA (RFS)	7
Konopke/2009	201	CRC	65/NR	Prospective	31	1-3 (94)	Liver	34.8/65.2	S (100)	MVA	MVA	6
Leal/2016	513	CRC	64.1/NR	Retrospective	37	1 (61.6)	Liver	100/0	S	MVA	MVA	7
Lin/2018	307	CRC	57.5/NR	Retrospective	31.7	1 (52.8)	Liver	66.4/33.6	S (100) ± RFA (10.1) ± Systemic tx	MVA	-	7
Liu/2010	52	CRC	70/NR	Retrospective	35.5	1 (58)	Liver	0/100	S + CT (100)	MVA	MVA (DFS)	6
Liu/2020	182	CRC	59.5/NR	Retrospective	32.5	1-3 (NR)	Liver	65/35	S ± CT	MVA	MVA (RFS)	6
Margonis/2015	334	CRC	50/NR	Retrospective	28.2	1-2 (NR)	Liver	54.8/45.2	S (100)	UVA	MVA (RFS)	6

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Margonis/2017	389	CRC	58.4/NR	Retrospective	20.8	1-2 (NR)	Liver	57.3/42.7	S ± Ablation (18.5) ± CT (71.5)	-	MVA (DFS)	6
Margonis/2019	718	CRC	62.3/NR	Retrospective	30.4	1-3 (36.4)	Liver	51.2/48.8	S ± Systemic tx	MVA	-	6
Mise/2010	98	CRC	62/NR	Retrospective	60	1-3 (68)	Various	0/100	S (100)	MVA	-	8
Miyamoto/2015	78	CRC	65/92	Retrospective	19.2	2 (37)	Various	-	-	UVA	-	6
Narayan/2020	357	CRC	60/NR	Prospective	127	1 (NR)	Liver	100/0	S ± HAI	-	UVA (RFS)	9
Negri/2005	135	CRC	60.5/82.2	Case-control	76.8	1 (60.7)	Various	100/0	CT (100)	MVA	-	8
Neofytou/2015	140	CRC	NR/NR	Retrospective	33	1 (41.4)	Liver	71.4/28.6	± S ± Systemic tx	UVA	UVA	6
Nojiri/2011	31	CRC	63.3/NR	Retrospective	62	1-2 (64.5)	Lung	3.2/96.8	S (100)	MVA	-	8
Park/2016	221	CRC	62/NR	Prospective	34.7	1 (73.3)	Lung	13.1/86.9	S (100) ± CT (79.6)	UVA	MVA (DFS)	6
Parkin/2013	5853	CRC	64/NR	Retrospective	20	1-3 (79)	Liver	37/50	Surgery (100)	MVA	-	5
Peng/2017	150	CRC	58/NR	Retrospective	36	1 (NR)	Liver	67/33	S ± CT (100)	MVA	MVA (RFS)	6
Peng/2018	140	CRC	55/NR	Retrospective	13	1-3 (79)	Liver	70/30	MWA (100)	-	MVA	6
Prasanna/2020	513	CRC	63/NR	Retrospective	NR	1 (NR)	Various	51/49	S ± CT	UVA	-	5
Rhu/2017	410	CRC	60/NR	Retrospective	34	1 (63)	Liver	-	S (100)	MVA	-	6
Ruzzo/2012	59	CRC	NR/100	Retrospective	NR	1 (64)	Various	0/100	CT (100)	UVA	UVA	5
Sasaki/2016	485	CRC	58.5//NR	Retrospective	31	1-3 (65)	Liver	57/43	S / RFA (100)	MVA	-	6
Sasaki/2017	251	CRC	57/NR	Retrospective	30.3	1-3 (NR)	Liver	-	S ± CT (100)	MVA	-	6
Shimizu/2019	160	CRC	66/NR	Retrospective	64	1-3 (88)	Lung	18/83	S (100)	MVA	-	7
Sorbye/2012	342	CRC	NR/98.8	Subgroup analysis of prospective random	NR	1 (53)	Liver	34.5/64.5	Various	-	UVA	5
Souglakos/2009	168	CRC	59/NR	Retrospective	NR	1-2 (53)	Various	-	CT (100)	MVA	MVA	5
Stang/2016	113	CRC	70/NR	Retrospective	99	1-3 (77)	Liver	21/79	RFA (100) CT (95)	MVA	MVA	8

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/ PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Stremtizer/2015	154	CRC	62/NR	Retrospective	34	1-2 (NR)	Liver	-	S (100)	MVA	MVA	6
Tarpgaard/2014	566	CRC	NR/96	Retrospective	37	0-1 (29)	Various	-	CT (100)	MVA	MVA	6
Van Cutsem/2004	1207	CRC	64/NR	Retrospective	NR	1 (25)	Various	76/24	CT (100)	MVA	-	5
Wang/2017	163	CRC	65/NR	Retrospective	37	1-2 (41)	Liver	82/18	S + CT (100)	MVA	MVA	6
Wei/2005	395	CRC	63/NR	Retrospective	31	1-3 (65)	Liver	51/49	S (100)	MVA	MVA	6
Xie/2018	332	CRC	58/NR	Retrospective	27.7	1 (65.2)	Various	72/18	Various	MVA	-	6
Yamashita/2017	74	CRC	59/NR	Retrospective	25	1 (74)	Liver	-	RFA/MWA + CT (100)	MVA	MVA	6
Zhao/2017	289	CRC	57/NR	Retrospective	34	1 (51)	Liver	66/34	S (100)	MVA	MVA	6
AI/2017	3245	Esophageal	66/NR	Retrospective	NR	1-3 (NR)	Various	-	-	MVA	-	5
Hashimoto/2010	466	Gastric	60/85	Retrospective	NR	1-2 (NR)	Various	71.7/28.3	CT (100)	UVA	-	5
Kadokura/2013	208	Gastric	64/81.3	Retrospective	26.9	1 (69.7)	Various	-	CT	MVA	-	6
Kim/2008	304	Gastric	54/73.3	Retrospective	NR	1 (81.2)	Various	-	CT (100)	MVA	-	5
Kimura/2019	103	Gastric	67/NR	Retrospective	NR	1-2 (89)	Various	-	CT (100)	MVA	-	5
Kinoshita/2015	256	Gastric	64/NR	Retrospective	65	1-2 (82.8)	Liver	41.4/58.6	S (100) + CT (32.8)	MVA	UVA	8
Kondoh/2018	50	Gastric	67/72	Retrospective	NR	1-2 (74)	Various	-	CT (100)	UVA	-	5
Makiyama/2018	444	Gastric	75/NR	Retrospective	28.7	1 (37.3)	Various	-	CT (100)	-	MVA	5
Wang/2016	310	Gastric	58/100	Retrospective	NR	1 (70.6)	Various	-	Various	MVA	-	5
Wang/2018	321	Gastric	57/85	Retrospective	32	0-1 (83)	Various	-	CT (100)	MVA	MVA	6
Liu/2015	981	HCC	52.5/NR	Prospective	32.7	1 (70.3)	Liver	-	± S (18.9) ± RFA (19.3) ± TACE (48.2)	-	MVA (RTDS)	7
Mazzafarro/2009	1556	HCC	55/NR	Retrospective	53	1 (26)	Liver	-	S (100)	MVA	-	7
Yoon/2010	52	HCC	49/NR	Retrospective	16.3	1 (75)	Lung	-	S (100)	MVA	-	6
Bollig/2020	283	Head & neck	59.8/NR	Retrospective	NR	1 (18.7)	Various	-	Various (100)	MVA	-	5
Lo/2017	120	Head & neck	NR/NR	Retrospective	51	1-3 (68.3)	LN's	-	S ± CT/RT	MVA	MVA (DFS)	8
Shen L/2015	505	Head & neck	NR/95	Retrospective	20	1 (18.8)	Various	100/0	CT ± RT (100)	MVA	-	6

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/ PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Shen L/2015 (2)	312	Head & neck	46/89.1	Retrospective	16	1-3 (62.2)	Bone	43.9 / 56.1	Various	MVA	-	6
Shinoda/2020	48	Liposarcoma	43/NR	Retrospective	27.5	1 (52.1)	Various	-	Various	UVA (DSS)	-	5
Li/2019	100	Lung	60/96.1	Retrospective	39	1-3 (13.7)	Brain	100/0	TKI ± CT	UVA	-	7
Prelaj/2019	193	Lung	65/88	Retrospective	43	1-3 (NR)	Various	-	IT (100)	UVA	MVA	7
Bian/2016	401	Melanoma	NR/83	Retrospective	35	1-4 (87)	CNS	-	SBRT (100)	MVA	-	7
Iacono/2019	162	Melanoma	NR/82	Retrospective	48	1-2 (66)	Various	-	Systemic tx (100)	MVA	-	7
Lee/2009	2247	Melanoma	51/NR	Retrospective	22.5	1-2 (67.4)	Various	-	-	MVA	-	6
Moreau/2012	115	Melanoma	59/NR	Retrospective	19	1-3 (64)	LNs	93/7	S (100)	MVA	MVA (DMFS)	6
Seremet/2019	85	Melanoma	57/91	Retrospective	21	1-2 (44.7)	Various	-	ICIs (100)	MVA	UVA	6
Weider/2012	855	Melanoma	62/NR	Retrospective	25	1-2 (74.7)	Various	-	Various	MVA	-	6
Robelin/2019	162	Neuroendocrine	61/90	Retrospective	56	1-2 (85)	Various	49/51	Various	MVA	UVA	7
Jiang/2015	347	NPC	48/100	Retrospective	NR	1 (28)	Various	100/0	CT (57.9) CT + RT (68.8) RT (3.7)	MVA	-	5
Nie/2017	209	NPC	45/81.3	Retrospective	16.6	1 (49.8)	Various	24.9/75.1	CT (100)	UVA	UVA	6
Beau-Faller/2019	228	NSCLC	NR/42	Retrospective	NR	1-2 (65)	Various	0/100	TKI (100)	MVA	MVA	5
Ding/2017	85	NSCLC	66/75	Retrospective	9.8	1-3 (48)	Various	-	TKI (94)	MVA	MVA	6
Liu/2018	216	NSCLC	57/NR	Retrospective	7	1-3 (NR)	Brain	-	RT ± Systemic tx	MVA	-	6
Niibe/2016	61	NSCLC	NR/100	Retrospective	NR	1-2 (89)	SNC	18/82	SBRT or SRS (100)	MVA	-	5
Paccagnella/2006	324	NSCLC	62/93.7	Phase 2-3	19	1 (30.5)	Various	100/0	CT (100)	UVA	-	6
Park/2019	517	NSCLC	64/NR	Retrospective	NR	1 (57)*	Various	100/0	Various	MVA	-	5
Shin/2016	1024	NSCLC	64/85.5	Retrospective	42.2	1 (14.8)*	Various	-	Systemic tx (100)	MVA	-	7
Sperduto/2016	1481	NSCLC	NR/69.2	Retrospective	NR	1-4 (81)	Brain	-	Various	MVA	-	5
Takahashi/2019	41	NSCLC	67/82	Retrospective	19.6	1 (57)	Bone	100/0	Various (100)	UVA	UVA	6
Tambo/2020	95	NSCLC	72/77.9	Retrospective	8.8	1-2 (80)	NR	-	Pembrolizumab (100)	MVA	MVA	5
Liu/2020	125	Osteosarcoma	17/100	Retrospective	NR	1-2 (72)	Lung	-	CT ± S	-	MVA (PRS)	5

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/ PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Bolim/2015	39	Pancreatic	NR/56	Retrospective	5	1 (56)	Various	-	RT (100)	MVA	-	6
Neron/2020	51	Phyllodes	56.4/95.9	Retrospective	62.1	1 (51)	Various	13.7/86.3	$\pm$ S (31.3) $\pm$ RT (31.9) $\pm$ CT (72.5)	UVA	-	7
Armstrong/2007	686	Prostate	68.5/88	Retrospective	70	1-2 (88)	Various	-	CT (100)	MVA	-	9
Tablazon/2019	837	Prostate	76/NR	Retrospective	26	1 (NR)	Bone	-	-	MVA	-	7
Zhang/2020	160	Prostate	68/NR	Retrospective	47.2	1-4 (39.4)	Bone	-	RT + OT (100)	UVA	-	7
Alt/2011	887	RCC	62.5/85	Retrospective	33.6	2 (16.5)	Various	58/42	S (14)	MVA	-	8
Atzpodiern/2003	425	RCC	NR/100	Retrospective	20	1-2 (82)	Various	0/100	Various	MVA	-	7
Beuselinck/2014	200	RCC	59/85	Retrospective	67	1 (83)	Various	38/62	Systemic tx (100)	UVA	UVA	8
Bossé/2020	3454 1061	RCC	62/81 61/97	Retrospective 2-cohort	34 24.9	1 (19.5) 1 (17.2)	NR	-	TKI (100)	MVA	-	6
Cai/2017	143	RCC	60/NR	Retrospective	22	1 (72.7)	Various	-	TKI (100)	UVA	UVA	6
Dai/2020	146	RCC	56.5/71.9	Retrospective	36	1 (56.8)	Various	45.9/54.1	TKI (100)	MVA	MVA	6
Fay/2018	4736	RCC	59.2/100	Pooled analysis of n=12 phase 2-3 trials	NR	1 (NR)	NR	-	-	MVA	-	6
Fujiwara/2020	45	RCC	62/82	Retrospective	26.4	1 (36)	NR	-	Nivolumab (100)	UVA	-	6
Furubayashi/2017	59	RCC	67/85	Retrospective	NR	1-2 (86)	Various	-	TKI (100)	MVA	-	5
Gu/2017	184	RCC	54	Retrospective	23.3	1 (85)	Various	-	Various	UVA	MVA	6
Ikeda/2018	116	RCC	66/NR	Retrospective	19.4	1 (66)	Various	-	TKI (100)	MVA	MVA	6
Ishihara/2017	118	RCC	NR/NR	Retrospective	NR	1 (NR)	Various	100/0	S	UVA	-	5
Keizman/2014	278	RCC	63/NR	Retrospective	55	1 (18)	Various	82/18	TKI $\pm$ S	UVA	UVA	8
Kim/2017	177	RCC	62/92.6	Retrospective	19.2	1-3 (NR)	Various	-	TKI (100)	MVA	UVA	6
Kwak/2007	186	RCC	58/86.5	Retrospective	17.4	1 (60.2)	Various	39.8/60.2	S $\pm$ ICIs	MVA	MVA	6
Kwak/2007 (2)	252	RCC	NR/61	Retrospective	17	1 (37)	Various	19/80	ICIs	MVA	MVA	6
Liou/2017	266	RCC	61/NR	Retrospective	12	1 (43)	Various	-	S (100)	MVA	-	6
Lu/2016	67	RCC	58/95.5	Retrospective	NR	1-4 (32.8)	Bone	-	TKI (100)	MVA	-	5

Table 1. Continued

Author/year	N° pts	Disease	Median age (years)/PS 0-1 (%)	Type of study	Median follow up (months)	Definition of OM (n° of lesions)/%	Site of OM	De novo / metachronous (%)	Treatment for OM (%)	OS (UVA or MVA)	PFS (UVA or MVA)	Quality
Richey/2011	188	RCC	60.8/65	Retrospective	6.9	1 (36)	Various	100/0	S + Systemic tx (100)	MVA	-	6
Schmidt/2005	321	RCC	51/NR	Retrospective	52	1-2 (60)	Various	-	Citokines (100)	UVA	-	7
Sharma/2015	93	RCC	61/76	Retrospective	13	1 (60)	Various	100/0	S ± Systemic tx (100)	MVA	-	6
Takagi/2019	71	RCC	66/99	Retrospective	NR	1 (45)	Various	-	TKI (100)	MVA	-	5
Thiery-Vuillemin/2017	224	RCC	67/82	Retrospective	18.3	1 (51)	Various	-	Systemic tx ± S (100)	UVA	-	6
Yamamoto/2018	51	RCC	65/80	Retrospective	NR	1 (45)	Various	-	TKI (100)	UVA	UVA	5
You/2016	325	RCC	NR/NR	Retrospective	NR	1 (37)	Various	55/45	S ± CT	MVA	MVA	5
Zhang/2019	287	RCC	56/NR	Retrospective	28	1 (53)	Various	-	S (100)	MVA	MVA	6
Dudek/2019	33	Sarcoma	55/NR	Retrospective	37	1-3 (72.7)	Lung	36/64	S (100)	UVA	-	7
Kawamoto/2020	98	Sarcoma	NR/NR	Retrospective	NR	1-2 (43.9)	Lung	-	Various	-	MVA (PMS)	
Nataraj/2016	102	Sarcoma	18/60	Retrospective	23	1-3 (31)	Lung	31/69	S ± CT (100)	MVA	MVA (EFS)	6
Shoushtari/2016	215	Sarcoma	56/26	Retrospective	175	1-2 (67)	Various	39/61	CT (100)	MVA	UVA	9
Stephens/2011	81	Sarcoma	43.5/NR	Retrospective	27	1-2 (33)	Lung	-	S (100)	MVA	-	7
Han/2011	61	SCLC	65/71	Phase 2	33.6	1-2 (NR)	Various	-	CT (100)	MVA	-	7
Shirasawa/2019	141	SCLC	70/62	Retrospective	NR	1-5 (34.7)	Various	100/0	CT (100)	MVA	-	5
Anraku/2003	133	Utherine	56/NR	Retrospective	40	1 (58)	Lung	6/94	S (100)	MVA	-	7
Bartosch/2016	130	Utherine	52/NR	Retrospective	48	1 (54)	Various	-	Various	MVA	-	7
Chen/2019	3981	Various	60.84/40.8	Retrospective	44.3	1 (16.5)	Various	-	Various (100)	MVA	-	7
de Baere/2015	566	Various	62.7/NR	Retrospective	35.5	1-2 (78)	Lung	-	RFA (100)	MVA	MVA	7
Dercle/2016	251	Various	52/NR	Retrospective	10.5	1-2 (40)	Various	-	ICIs (100)	MVA	-	6
Silva/2019	61	Various	66.3/NR	Retrospective	13.58	1-5 (35)	Spine	-	SBRT (100)	-	MVA (LC 1y)	6

*M1b single extratoracic organ; CNS, central nervous system; CRC, colorectal cancer; CT, chemotherapy; DMFS, distant metastasis-free survival; DSS, disease-specific survival; EFS, event-free survival; HAI, hepatic artery infusion; HCC, hepatocellular carcinoma; ICIs, immune checkpoint inhibitors; LN, lymph node; MVA, microwave ablation; NPC, nasopharyngeal carcinoma; NSCLC, non-small-cell lung cancer; OM, oligometastatic disease; OS, overall survival; OT, ormonotherapy; PFS, progression-free survival; PMS, post-metastasis survival; PRS, post-relapse survival; PS, performance status; RCC, renal cell carcinoma; RFA, radiofrequency ablation; RES, relapse-free survival; RTDS, recurrence to death survival; S, surgery; RT, radiotherapy; SBRT, stereotactic body radiotherapy; SCLC, small-cell lung cancer; SRS, stereotactic radiosurgery; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TTP, time to progression; TX, therapy; UVA, univariate analysis.

Figure 2. Progression-free survival of oligo- compared to non-oligometastatic cancers.

Progression-free survival was better in patients with OM disease (HR = 0.62, 95% CI 0.57–0.68; $P < .01$; $n = 69$ studies; Figure 2). Additionally, in the OS analysis, OM cancers were associated with a better OS (HR = 0.65, 95% CI 0.62–0.68; $P < .01$; $n = 161$ studies; Figure 3). Results were significant for all analyzed disease subgroups except biliary tract cancer and cervical cancer (only three studies included). In colorectal (CRC), breast, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), which constituted the more representative series, the reduction in the risk of death for OM patients were 35, 38, 30 and 42%, respectively (Figure 3). Timing of onset did not influence the risk of death. Most studies reported OS analysis for up to three metastases (152 out of 161 studies). After exclusion of eight studies that reported outcomes for up to five metastases the final results remained unchanged (HR = 0.64, 95% CI 0.61–0.67; $P < .01$). No cut-off was associated with a better outcome (1 vs 2 vs 1-2 vs 1-3 metastases).

Risk of bias through Begg's funnel plot was not significant for the OS analysis. Conversely, Egger's test showed evidence of bias ($P < .01$) (Figure 4). Trim and Fill analysis incorporated 29 missing studies. The overall effect measure (95% CI) based on this analysis was 0.7 (0.67–0.73), which became slightly weaker compared to the originally reported overall effect measure. Compared with cancers with more than three to five metastases, high-certainty evidence indicates OM tumors are associated with better prognosis in particular for CRC, breast, NSCLC and RCC. Despite the subgroup difference is not significant likely for less studies included in other groups, the results for these 4 cancers remain robust.

Discussion

The definition of oligometastatic refers to malignancies with a limited metastatic spread which may be amenable of radical treatment for both primary and each distant site, and that generally have a better prognosis compared to polymetastatic cancers. A very recently published paper clearly explains the timely clonal evolution of somatic mutations and consequently the metastatic process of many cancer types.¹¹ It may be hypothesized that OM cancer is associated with a more indolent spread and therefore may represent a less fatal disease. With the expansion of the oncological

Figure 3. Overall survival of oligo- compared to non-oligometastatic cancers.

1.1.5 Colorectal

Figure 3. (continued)

1.1.6 Esophageal

Ai 2017	-1.1712	0.3065	0.4%	0.31 [0.17, 0.57]
Subtotal (95% CI)			0.4%	0.31 [0.17, 0.57]
Heterogeneity: Not applicable				
Test for overall effect: $Z = 3.82$ ($P = 0.0001$)				

1.1.7 Gastric

Hashimoto 2010	-0.8162	0.1531	0.8%	0.54 [0.40, 0.73]
Kadokura 2013	-0.4463	0.1797	0.7%	0.64 [0.45, 0.91]
Kim JG 2008	-0.1912	0.1594	0.8%	0.83 [0.60, 1.13]
Kimura 2019	-0.4005	0.2506	0.5%	0.67 [0.41, 1.09]
Kinoshita 2015	-0.8463	0.1876	0.7%	0.43 [0.30, 0.62]
Kondoh 2018	-0.1625	0.3245	0.3%	0.85 [0.45, 1.61]
Wang 2016	-0.3857	0.1468	0.9%	0.68 [0.51, 0.91]
Wang 2018	-0.3425	0.1396	0.9%	0.71 [0.54, 0.93]
Subtotal (95% CI)			5.7%	0.65 [0.56, 0.75]
Heterogeneity: $\tau^2 = 0.01$; $\chi^2 = 9.83$, $df = 7$ ($P = 0.20$); $I^2 = 29\%$				
Test for overall effect: $Z = 5.86$ ($P < 0.00001$)				

1.1.8 Head & Neck

Jiang 2015	-0.0619	0.2082	0.6%	0.94 [0.63, 1.41]
Lo 2017	-0.2744	0.2452	0.5%	0.76 [0.47, 1.23]
Nie 2017	-0.2485	0.1876	0.7%	0.78 [0.54, 1.13]
Shen L 2015	-0.47	0.1676	0.8%	0.63 [0.45, 0.87]
Shen L 2015 (2)	-0.47	0.1676	0.8%	0.63 [0.45, 0.87]
Subtotal (95% CI)			3.4%	0.72 [0.61, 0.85]
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 3.29$, $df = 4$ ($P = 0.51$); $I^2 = 0\%$				
Test for overall effect: $Z = 3.94$ ($P < 0.0001$)				

1.1.9 HCC

Mazzaferro 2009	-0.4155	0.1119	1.0%	0.66 [0.53, 0.82]
Yoon 2010	-0.2614	0.7291	0.1%	0.77 [0.18, 3.21]
Subtotal (95% CI)			1.1%	0.66 [0.53, 0.82]
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 0.04$, $df = 1$ ($P = 0.83$); $I^2 = 0\%$				
Test for overall effect: $Z = 3.72$ ($P = 0.0002$)				

1.1.10 Melanoma

Bian 2016	-0.3285	0.186	0.7%	0.72 [0.50, 1.04]
Iacono 2019	0.1484	0.3279	0.3%	1.16 [0.61, 2.21]
Lee 2009	-0.2627	0.0287	1.4%	0.77 [0.73, 0.81]
Moreau 2012	-0.7985	0.2878	0.4%	0.45 [0.26, 0.79]
Seremet 2019	-0.8675	0.3941	0.2%	0.42 [0.19, 0.91]
Weide 2012	-0.4155	0.1732	0.7%	0.66 [0.47, 0.93]
Subtotal (95% CI)			3.9%	0.71 [0.59, 0.85]
Heterogeneity: $\tau^2 = 0.02$; $\chi^2 = 8.16$, $df = 5$ ($P = 0.15$); $I^2 = 39\%$				
Test for overall effect: $Z = 3.75$ ($P = 0.0002$)				

1.1.11 Neuroendocrine

Robelin 2019	-0.1508	0.4317	0.2%	0.86 [0.37, 2.00]
Subtotal (95% CI)			0.2%	0.86 [0.37, 2.00]
Heterogeneity: Not applicable				
Test for overall effect: $Z = 0.35$ ($P = 0.73$)				

1.1.12 NSCLC

Beau-Faller 2019	-0.9163	0.2198	0.6%	0.40 [0.26, 0.62]
Ding 2017	-0.478	0.3537	0.3%	0.62 [0.31, 1.24]
Li 2019	-0.47	0.3416	0.3%	0.63 [0.32, 1.22]
Liu 2018	-0.0726	0.2409	0.5%	0.93 [0.58, 1.49]
Niibe 2016	-0.7985	0.5605	0.1%	0.45 [0.15, 1.35]
Paccagnella 2006	-0.2614	0.1534	0.8%	0.77 [0.57, 1.04]
Park 2019	-0.478	0.0714	1.3%	0.62 [0.54, 0.71]
Shin 2016	-0.2744	0.1206	1.0%	0.76 [0.60, 0.96]
Sperduto 2016	-0.1985	0.0735	1.2%	0.82 [0.71, 0.95]
Takahashi 2019	-0.3011	0.3676	0.3%	0.74 [0.36, 1.52]
Subtotal (95% CI)			6.4%	0.70 [0.60, 0.80]
Heterogeneity: $\tau^2 = 0.02$; $\chi^2 = 17.06$, $df = 9$ ($P = 0.05$); $I^2 = 47\%$				
Test for overall effect: $Z = 4.94$ ($P < 0.00001$)

Figure 3. (continued)

1.1.13 Pancreatic

Bolm 2015	-0.7985	0.3061	0.4%	0.45 [0.25, 0.82]
Subtotal (95% CI)			0.4%	0.45 [0.25, 0.82]

Heterogeneity: Not applicable

Test for overall effect: $Z = 2.61$ ($P = 0.009$)**1.1.14 Prostate**

Armstrong 2007	-0.4943	0.144	0.9%	0.61 [0.46, 0.81]
Tablazon 2019	-0.478	0.797	0.1%	0.62 [0.13, 2.96]
Subtotal (95% CI)			1.0%	0.61 [0.46, 0.81]

Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 0.00$, $df = 1$ ($P = 0.98$); $I^2 = 0\%$ Test for overall effect: $Z = 3.48$ ($P = 0.0005$)**1.1.15 RCC**

Alt 2011	0.077	0.1282	1.0%	1.08 [0.84, 1.39]
Atzpodien 2003	-0.3425	0.1589	0.8%	0.71 [0.52, 0.97]
Beuselinck 2014	-0.4308	0.2606	0.5%	0.65 [0.39, 1.08]
Cai 2017	-0.5108	0.2198	0.6%	0.60 [0.39, 0.92]
Fay 2018	0.4253	0.1114	1.0%	1.53 [1.23, 1.90]
Furubayashi 2017	-1.8971	0.5708	0.1%	0.15 [0.05, 0.46]
Gu 2017	-0.3285	0.2398	0.5%	0.72 [0.45, 1.15]
Ikeda 2018	-0.7985	0.2606	0.5%	0.45 [0.27, 0.75]
Ishihara 2017	-0.6539	0.3945	0.2%	0.52 [0.24, 1.13]
Keizman 2014	-0.0513	0.1782	0.7%	0.95 [0.67, 1.35]
Kim SH 2017	-0.7985	0.2421	0.5%	0.45 [0.28, 0.72]
Kwak 2007	-0.5621	0.4005	0.2%	0.57 [0.26, 1.25]
Kwak 2007 (2)	-0.844	0.2975	0.4%	0.43 [0.24, 0.77]
Liou 2017	-1.4271	0.275	0.4%	0.24 [0.14, 0.41]
Lu 2016	-1.2413	0.4975	0.2%	0.29 [0.11, 0.77]
Richey 2011	-0.5482	0.2167	0.6%	0.58 [0.38, 0.88]
Schmidt 2005	-0.47	0.1139	1.0%	0.63 [0.50, 0.78]
Sharma 2015	-0.755	0.2643	0.5%	0.47 [0.28, 0.79]
Takagi 2019	-1.3471	0.4389	0.2%	0.26 [0.11, 0.61]
Thiery-Vuillemin 2017	-0.3945	0.1524	0.8%	0.67 [0.50, 0.91]
Yamamoto 2018	-0.844	0.4167	0.2%	0.43 [0.19, 0.97]
You 2016	-0.734	0.1612	0.8%	0.48 [0.35, 0.66]
Zhang 2019	-0.1744	0.1802	0.7%	0.84 [0.59, 1.20]
Subtotal (95% CI)			12.6%	0.58 [0.47, 0.71]

Heterogeneity: $\tau^2 = 0.18$; $\chi^2 = 116.31$, $df = 22$ ($P < 0.00001$); $I^2 = 81\%$ Test for overall effect: $Z = 5.28$ ($P < 0.00001$)**1.1.16 Sarcoma**

Dudek 2019	-0.7985	0.4967	0.2%	0.45 [0.17, 1.19]
Nataraj 2016	-1.5141	0.5161	0.2%	0.22 [0.08, 0.60]
Shoushtari 2016	-0.4005	0.1596	0.8%	0.67 [0.49, 0.92]
Stephens 2011	-0.4943	0.3135	0.4%	0.61 [0.33, 1.13]
Subtotal (95% CI)			1.5%	0.54 [0.37, 0.80]

Heterogeneity: $\tau^2 = 0.06$; $\chi^2 = 4.59$, $df = 3$ ($P = 0.20$); $I^2 = 35\%$ Test for overall effect: $Z = 3.07$ ($P = 0.002$)**1.1.17 SCLC**

Han 2011	-0.7985	0.2999	0.4%	0.45 [0.25, 0.81]
Shirasawa 2019	-0.5798	0.1116	1.0%	0.56 [0.45, 0.70]
Subtotal (95% CI)			1.4%	0.55 [0.44, 0.67]

Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 0.47$, $df = 1$ ($P = 0.49$); $I^2 = 0\%$ Test for overall effect: $Z = 5.80$ ($P < 0.00001$)**1.1.18 Uterine**

Anraku 2003	-0.5108	0.4074	0.2%	0.60 [0.27, 1.33]
Bartosch 2016	-0.7765	0.2533	0.5%	0.46 [0.28, 0.76]
Subtotal (95% CI)			0.7%	0.50 [0.32, 0.76]

Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 0.31$, $df = 1$ ($P = 0.58$); $I^2 = 0\%$ Test for overall effect: $Z = 3.27$ ($P = 0.001$)**1.1.19 Other**

Chen 2019	-0.4005	0.0438	1.4%	0.67 [0.61, 0.73]
de Baere 2015	-0.4829	0.1725	0.8%	0.62 [0.44, 0.87]
Dercle 2016	-0.0408	0.2842	0.4%	0.96 [0.55, 1.68]
Subtotal (95% CI)			2.5%	0.67 [0.62, 0.73]

Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 1.83$, $df = 2$ ($P = 0.40$); $I^2 = 0\%$ Test for overall effect: $Z = 9.47$ ($P < 0.00001$)

Total (95% CI)			100.0%	0.65 [0.62, 0.68]
----------------	--	--	--------	-------------------

Heterogeneity: $\tau^2 = 0.03$; $\chi^2 = 550.25$, $df = 160$ ($P < 0.00001$); $I^2 = 71\%$ Test for overall effect: $Z = 20.17$ ($P < 0.00001$)Test for subgroup differences: $\chi^2 = 22.10$, $df = 18$ ($P = 0.23$), $I^2 = 18.6\%$

Figure 3. (continued)

Figure 4. Funnel plot of publication bias for overall survival analysis showing standard error by log hazard ratio.

armamentarium, many efforts have been made over the years to improve outcomes of patients with minimal metastatic burden.

We have performed the most exhaustive systematic review of the literature to quantify the prognostic value of OM stage in various cancers. Overall, OM cancer patients have a risk of death and progression that is a third less than the polymetastatic counterpart. The OM state is frequently calculated as an independent favorable prognostic variable, which means that these patients do well independent from other clinical-pathological characteristics. The effect size was calculated from 173 studies including more than 100,000 patients. The final results were similar in all the most frequent histologies including CRC, breast cancer, NSCLC, RCC and sarcoma with inferior survival in OM gastric, melanoma and head and neck cancers.

Prognosis of OM cancer may be also different according to site of oligometastases. For example in CRC, breast and RCC lung metastases have a generally more favourable outcome than liver (or peritoneal ones in CRC). In our series, sites of oligometastases were mixed or not described at all so a subgroup analysis was not performed.¹²

There is also evidence from randomized clinical trials¹³⁻¹⁵ that ablative therapies improve survival in patients with OM cancer. For example, in some cancers small randomized studies¹³⁻²¹ already provide evidence of survival improvement in patients that received both systemic and local therapies compared to those that received systemic therapies alone. As a matter of fact, resection of colorectal cancer liver metastases nowadays represents an essential curative option and a primary endpoint in multiple clinical trials.¹³ Furthermore, Gomez *et al.*¹⁴ found that in OM NSCLCs, adding local consolidative therapy to active oligometastases and to primary disease may improve OS from 17 to 41 months. Also, in RCC the treatment of indolent lung metastases may permit delaying the start of systemic treatment and obtain an excellent control.¹⁵ A large burden of evidence now supports local therapy for minimal oligoprogressive cancers treated with targeted therapies or immunotherapy. Here, metastases-directed therapy could delay the switch of systematic therapy by radical local treatment of all progressive metastatic sites.^{16,17} With the advent of immunotherapy, the combination of immune check point inhibitors and radiotherapy to single OM lesions may facilitate a potentiation of the immune response, increasing the chances of achieving an abscopal effect. This term describes an event in which focalized radiotherapy discharge systemic anti-tumoral action that can result in distant responses.¹⁸ For example, in lung cancer the combination has a good safety profile and achieves high rates of local control and greater chances of obtaining abscopal responses than radiotherapy alone, with a relevant impact on outcome.¹⁹ Oligometastatic cancers can also regarded as extended locoregional disease if, after proper conversion therapy, all sites of metastases and primary tumor may be radically resected with curative purposes. Such a strategy has been employed in largely incurable cancers as gastric and pancreatic carcinomas where selected cases with small liver-limited recurrences were managed with surgery.^{20,21} Melanoma and head and neck OM cancers are also associated with better prognosis. In these settings isolated recurrences (lymph nodes, lung nodules or brain metastases) may be radically treated with surgery or radiotherapy.

This meta-analysis has several limitations. First, our review does not evaluate the absolute benefit of any local treatment and the prognosis and management of oligoprogressive disease or down staged polymetastases to an OM state. Second, the literature search covered a large lifetime span and may include older series where radiological evaluation did not include more advanced modalities that can now increase the accuracy of oligometastases detection. Third, most of studies have an observational design and outcome was retrospectively analysed. Likely publication bias may influenced the prognosis of this population. Finally, the optimal number of lesions defining the OM state cannot be defined in this paper.

A consensus paper of EORTC and ESTRO societies attempted to provide definitions of various OM conditions either naïve or attained after therapy and either synchronous or metachronous.²²

Some large, randomized studies have included local therapies for OM cancers. An NRG Oncology randomized phase II/III trial study compares therapy with stereotactic radiosurgery and/or surgery with standard of care therapy alone in treating patients with breast cancer that has one or two locations in the body (limited metastatic) that are previously untreated. The PREST study will assess the efficacy of ablative radiotherapy (stereotactic body radiotherapy applied to all oligometastases) administered to all tumor sites (metastases and prostate if applicable), in oligometastatic hormone-sensitive prostate cancer patients. Finally, an ECOG-ACRIn phase III study compared standard chemotherapy to consolidative radiotherapy in patients with oligometastatic HER2 negative esophageal and gastric adenocarcinoma (<https://clinicaltrials.gov/ct2/show/NCT02364557>; <https://clinicaltrials.gov/ct2/show/NCT04115007>; <https://clinicaltrials.gov/ct2/show/NCT04248452>). In all ongoing studies the aim is the optimal timing (after a good shrinkage during systemic therapy) and integration of systemic medical therapy and local ablation/resection with the scope of improving long-term survivals.

Conclusions

In conclusion, this meta-analysis tried to quantify the prognosis associated with OM compared to cancers with more extensive diffusion. Based on our findings, we suggest that every metastatic patient should be accurately evaluated for the number of distant sites of disease, and a treatment strategy that involves both the primary and the metastases should be carefully considered. Patients could be reassured about their life expectancy and about the possibility of integrate both systemic and local therapy with the hope, in certain cases, for definitive cure. In others, focal treatment on the metastases may delay the immediate use of more toxic drugs (for example in elderly or indolent diseases). Also, we propose that these patients should be stratified when included in clinical trials and dedicated studies should be designed.

Data availability

Extended data

Mendeley Data: Extended data for ‘Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies’.

<http://dx.doi.org/10.17632/8kycvdp6v.1>.¹⁰

This project contains the following extended data:

Supplementary Table 1: List of included studies.

Reporting guidelines

Mendeley Data: PRISMA checklist for ‘Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies’.

<http://dx.doi.org/10.17632/8kycvdp6v.1>.¹⁰

Data are available under the terms of the Creative Commons Attribution 4.0 license (CC-BY 4.0).

References

1. Hellman S, Weichselbaum RR: **Oligometastases.** *J Clin Oncol.* 1995; **13**(1): 8–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Weichselbaum RR, Hellman S: **Oligometastases revisited.** *Nat Rev Clin Oncol.* 2011; **8**(6): 378–382.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Chalkidou A, Macmillan T, Grzeda MT, *et al.*: **Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.** *Lancet Oncol.* 2021 Jan; **22**(1): 98–106.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Donini M, Buti S, Massari F, *et al.*: **Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.** *Expert Rev Anticancer Ther.* 2020 Jun; **20**(6): 491–501. Epub 2020 Jun 1.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Glicksman RM, Metser U, Vines D, *et al.*: **Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.** *Eur Urol.* 2021 Mar 5; S0302-2838(21)00151-2. Epub ahead of print.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Palma DA, Olson R, Harrow S, *et al.*: **Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.** *Lancet.* 2019 May 18; **393**(10185): 2051–2058.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Begg CB, Mazumdar M: **Operating Characteristics of A Bank Correlation Test for Publication Bias.** *Biometrics.* 1994; **50**(4): 1088–1101.
[PubMed Abstract](#)
8. Shi L, Lin L, Omboni S: **The trim-and-fill method for publication bias: Practical guidelines and recommendations based on a large database of meta-analyses.** *Med (United States).* 2019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Review Manager (RevMan) [Computer program]: **Version 5.3.** Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
10. Petrelli F, *et al.*: **Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies.** *Mendeley Data.* 2021.
[Publisher Full Text](#)
11. Gerstung M, Jolly C, Leshchiner I, *et al.*: **The evolutionary history of 2,658 cancers.** *Nature.* 2020 Feb; **578**(7793): 122–128. Epub 2020 Feb 6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Franko J, Shi Q, Meyers JP, *et al.*: **Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.** *Lancet Oncol.* 2016 Dec; **17**(12): 1709–1719.
13. Fong Y, Fortner J, Sun RL, *et al.*: **Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.** *Ann Surg.* 1999; **230**(3): 309–321.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Gomez DR, Tang C, Zhang J, *et al.*: **Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.** *J Clin Oncol.* 2019 Jun 20; **37**(18): 1558–1565. Epub 2019 May 8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Zhang Y, Schoenhals J, Christie A, *et al.*: **Stereotactic Ablative Radiation Therapy (SABR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.** *Int J Radiat Oncol Biol Phys.* 2019 Oct 1; **105**(2): 367–375. Epub 2019 Aug 1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Kroeze SGC, Schaule J, Fritz C, *et al.*: **Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOASTT' database.** *Radiat Oncol.* 2021 Jan 6; **16**(1): 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Deek MP, Tapparra K, Phillips R, *et al.*: **Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.** *Eur Urol Oncol.* 2020 Jun 11; S2588–9311 (20)30058-4. Epub ahead of print.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Mole RJ: **Whole body irradiation - Radiology or medicine?** *Br J Radiol.* 1953; **26**: 234–241.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Chicas-Sett R, Morales-Orue I, Castilla-Martinez J, *et al.*: **Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.** *Int J Mol Sci.* 2019 May 2; **20**(9): 2173.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. De Simoni O, Scarpa M, Tonello M, *et al.*: **Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis.** *Cancers (Basel).* 2020 Nov 17; **12**(11): 3402.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Zhang F, Huang X, Song Y, *et al.*: **Conversion Surgery for Stage IV Gastric Cancer.** *Front Oncol.* 2019 Nov 7; **9**: 1158.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Guckenberger M, Lievens Y, Bouma AB, *et al.*: **Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.** *Lancet Oncol.* 2020 Jan; **21**(1): e18–e28.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 3

Reviewer Report 22 November 2021

<https://doi.org/10.5256/f1000research.77989.r100190>

© 2021 Campana L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Luca G. Campana

¹ Department of Surgery, Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK

² Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK

The authors of this report deserve praise for their extensive work. The data presented are intriguing and raise some intriguing questions.

- For the included studies, it would be interesting to know the comparator group and its tumour burden. This information would help to appreciate the magnitude of the differences in outcome.
- Additionally, one of the original questions raised with the introduction of the oligometastatic concept relates to the feasibility of local or locoregional treatment in a subset of patients with indolent disease. In this regard, I would present this information as a separate column in Table 1.
- Always in Table 1, the columns on OS and PFS present rather generic information. Therefore, I would suggest including the specific outcomes. Also, the column on Age and PS should be split. Finally, the content of the column "Type of study" should be homogenised.
- Further, the authors need to consider the time bias because modern imaging technologies increase the number of patients labelled as oligometastatic.
- It would be essential to distinguish between different types of oligometastatic disease (e.g., indolent progressive and minimal residual disease after previous treatments). In this regard, in Table 1, the column "De novo or metachronous" seems to provide this information, but it is not entirely clear.
- Please include the authors cited in Table 1 in the reference list.

Minor comments

Abstract

Please revise and use terms consistently (e.g. avoid “overall mortality in OM”). In addition, the conclusions should be reformulated; in particular, the last sentence should be more focused on the results presented.

Introduction

Please revise the language and, wherever possible, shorten the text (e.g. the first sentence is superfluous in this context). Also, please check some definitions such as “prognostic survival” and “with up to three to five metastatic sites.”

Methods

Please adjust the definition of polymetastatic accordingly.

Results

Figure 1: More than 2,000 reports were excluded from the analysis. The reason needs to be clarified.

Table 1 should indicate more clearly the prevalence of patients with oligometastatic disease.

Page 14: “Timing of onset did not influence the risk of death”. The authors should better explain this finding.

Discussion

The discussion could be improved by discussing some general issues first (challenges in the definition of OM, changing scenario in terms of diagnostic tools and available treatments) and then presenting some reflections on the cancer types where the effect of OM on OS was more prominent. For instance, the criterium of OM disease has been long applied in surgical oncology for selecting patients with lung metastases for surgical resection or patients with peritoneal carcinomatosis for cytoreduction and intraperitoneal chemotherapy.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Surgical oncology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 May 2022

Fausto Petrelli

The authors of this report deserve praise for their extensive work. The data presented are intriguing and raise some intriguing questions.

- For the included studies, it would be interesting to know the comparator group and its tumour burden. This information would help to appreciate the magnitude of the differences in outcome.

Data not available (comparator is the non-oligometastatic group but is not

known site and number of metastases, for definition > 3-5 metastases).

- Additionally, one of the original questions raised with the introduction of the oligometastatic concept relates to the feasibility of local or locoregional treatment in a subset of patients with indolent disease. In this regard, I would present this information as a separate column in Table 1.

Data not available.

- Always in Table 1, the columns on OS and PFS present rather generic information. Therefore, I would suggest including the specific outcomes. Also, the column on Age and PS should be split. Finally, the content of the column "Type of study" should be homogenised.

OS and PFS are not generic but the exact outcomes (what is the meaning of specific outcomes?). Age and PS were split.

- Further, the authors need to consider the time bias because modern imaging technologies increase the number of patients labelled as oligometastatic. **Sentence added in discussion.**
- It would be essential to distinguish between different types of oligometastatic disease (e.g., indolent progressive and minimal residual disease after previous treatments). In this regard, in Table 1, the column "De novo or metachronous" seems to provide this information, but it is not entirely clear.

Data were not available. Only the information reported were extractable.

- Please include the authors cited in Table 1 in the reference list.

Due to the high number of studies, ref list is reported in a separated file.

Minor comments

Abstract

Please revise and use terms consistently (e.g. avoid "overall mortality in OM"). In addition, the conclusions should be reformulated; in particular, the last sentence should be more focused on the results presented.

OK sentence modified.

Introduction

Please revise the language and, wherever possible, shorten the text (e.g. the first sentence is superfluous in this context). Also, please check some definitions such as "prognostic survival" and "with up to three to five metastatic sites."

OK sentence modified. Sentences cancelled.

Methods

Please adjust the definition of polymetastatic accordingly.

OK, sentence modified.

Results

Figure 1: More than 2,000 reports were excluded from the analysis. The reason needs to be

clarified.

OK reason included.

Table 1 should indicate more clearly the prevalence of patients with oligometastatic disease.

Data already included in the table by the authors.

Page 14: "Timing of onset did not influence the risk of death". The authors should better explain this finding.

OK, sentence modified.

Discussion

The discussion could be improved by discussing some general issues first (challenges in the definition of OM, changing scenario in terms of diagnostic tools and available treatments) and then presenting some reflections on the cancer types where the effect of OM on OS was more prominent. For instance, the criterium of OM disease has been long applied in surgical oncology for selecting patients with lung metastases for surgical resection or patients with peritoneal carcinomatosis for cytoreduction and intraperitoneal chemotherapy.

OK sentences added.

Competing Interests: none

Reviewer Report 22 November 2021

<https://doi.org/10.5256/f1000research.77989.r100189>

© 2021 Baratti D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dario Baratti

Peritoneal Surface Malignancies Unit, Colorectal Surgical Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

The authors have thoroughly addressed all my comments, resulting in a stronger paper.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Peritoneal surface malignancies, advanced colorectal cancer

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2

Reviewer Report 22 September 2021

<https://doi.org/10.5256/f1000research.58374.r93920>

© 2021 Baratti D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dario Baratti

¹ Peritoneal Surface Malignancies Unit, Colorectal Surgical Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

² Peritoneal Surface Malignancies Unit, Colorectal Surgical Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

The authors present the results of their systematic review and meta-analysis assessing the prognostic impact of oligometastatic disease on adult patients with solid tumors, as compared with a more diffuse metastatic spread. Overall and progression-free survival were significantly longer in patients with 3-to-5 metastatic lesions, irrespective of anatomic site. This may sound quite obvious in modern oncology, but the authors were able to provide a large amount of clinical data to support such an assumption.

Comments:

Abstract:

- In the Introduction, the main topic of this literature review was described concisely but exhaustively.
- In the Conclusions, please use the term "oligometastatic disease (or OM)" instead of "oligometastases".

Methods:

- The methodology of literature search and data extraction, paper selection criteria, and statistical analyses are thoroughly described. The review was carried out according to international guidelines (PRISMA). Please, clarify if papers not in English language studies were included.
- Also, the Newcastle-Ottawa Scale (NOS) might be briefly described, as a number of readers may be not familiar with it.

Results:

- In the Results section, the authors state that the reduction in the risk of death for oligometastatic patients was 35%, 38%, 30%, and 42% for colorectal, breast, non-small cell lung cancer, and renal cell carcinoma (RCC), respectively. In another part of this section, they state that compared with cancers with more than three to five metastases, "high-certainty evidence indicates OM tumors are associated with better prognosis in particular for CRC, breast, NSCLC and RCC". However, was such a difference significant? In agreement with Reviewer 1, I would suggest to group studies according to histology, and to graphically depict the risk of oligometastatic vs. more advanced disease for each of the four tumors mentioned above.

- Figure 1: Please, clarify in the Methods section what “Records marked as ineligible by automation tools” means.
- Figure 2 and 3: Please, refer to my comments about the Results section.

Discussion:

- The Discussion was improved according to the suggestions of Reviewer 1, resulting in a stronger manuscript. There is an additional concept that I would address in the paper: the fact that the site of metastatic disease may affect patient prognosis, in addition to the number of metastatic lesions. In colorectal cancer, peritoneal metastases are associated with worse prognosis as compared with liver metastases, and lung metastases are associated with better prognosis. Furthermore, specific areas within the same organ may be related to a worse prognosis, e.g. a metastasis involving the hepatic hilum may be worse than a subcapsular liver metastasis.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Peritoneal surface malignancies, advanced colorectal cancer

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 26 Sep 2021

Fausto Petrelli

I have the comments of Reviewer 2:

- I changed the conclusion of the abstract as requested.
- I included a statement in the Methods section about the exclusion of non-English language papers and the NOS scale definition.
- I have modified Fig. 1.

- I have provided a new Fig. 5 with subgroup analysis according to disease histology.
- In the discussion section, I provided a brief discussion about the site of oligometastases (lung vs others), in particular for CRC.

Competing Interests: No competing interests were disclosed.

Author Response 28 Oct 2021

Fausto Petrelli

My responses to the comments of Reviewer 2:

- I changed the conclusion of the abstract as requested.
- I included a statement in the Methods section about the exclusion of non-English language papers and the NOS scale definition.
- I have modified Fig. 1.
- I have provided a new Fig. 5 with subgroup analysis according to disease histology.
- In the discussion section, I provided a brief discussion about the site of oligometastases (lung vs others), in particular for CRC.

Competing Interests: No competing interests were disclosed.

Version 1

Reviewer Report 30 June 2021

<https://doi.org/10.5256/f1000research.55843.r87329>

© 2021 Campana L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Luca G. Campana

¹ Department of Surgery, Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK

² Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK

³ Department of Surgery, Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation

Trust, Manchester, UK

⁴ Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK

⁵ Department of Surgery, Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK

⁶ Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK

The authors of this systematic review and meta-analysis assessed the influence of oligometastatic disease status on OS and PFS in adult patients with solid tumours. To do this, they carried out an extensive literature review including all types of studies with at least ten patients with any histology. Patients with OM disease were found to have significantly longer PFS and OS if they had CRC, BC, NSCLC, RCC, and sarcoma.

The literature screening was conducted according to the standard recommendations and the subsequent analysis is methodologically robust. Going across several histotypes, the paper provides a big, and for certain aspects, unique picture of the prognosis of patients with OM. At the same time, however, it makes it challenging summarising and discussing the results.

Here you can find some comments that you may find useful to improve this review:

- In the Abstract, I would mention the histotypes in which the OM status do not correlate with patient outcome. Also, in the Conclusions part, second sentence: this seems to be unrelated to the results presented and anyway not applicable in all cases (consider rephrasing/changing).
- The Introduction needs some input because sentences do not always follow a clear pattern. For instance, there are some general considerations regarding tumour progression, tumour staging according to the TNM, detailed results of a specific trial. It needs to be more homogeneous.
- Given the positive results with ablative therapies in patients with OM disease, the authors should explain what this meta-analysis adds to the literature.
- From the Introduction (and Methods) it is not clear what the definition adopted of OM disease is ("up to 3 to 5" metastatic sites). In this regard, is a patient with 6 liver metastases still considered "oligometastatic"?
- The great majority of the studies were retrospective in nature. This should be clearly stated and critically discussed as well.
- Did the authors detect any imbalance in treatment intensity between OM vs. non-OM patients?
- Table 1, 8th column: some of the included studies have "various" sites of OM. I think this information should be specified in order to be consistent with the inclusion criteria.
- The studies could be regrouped according to the histology. The same could apply to Figure 2 and Figure 3.

- The prognosis of patients with gastric cancer, melanoma, and head and neck cancer should be discussed in light of the results presented.
- In the Discussion, it is not entirely clear if the authors consider the OM status an opportunity to spare patients from systemic treatment or an opportunity to pursue combined treatment. Again, this should be discussed in light of the results presented.
- In the Discussion, the last paragraph seems more like a list of ongoing trials, including some form of local therapies over standard systemic treatment. How does this relate to the findings of the present study? Please discuss.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Partly

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Surgical oncology, locoregional therapies (limb perfusion/infusion, intraperitoneal chemotherapy, electrochemotherapy), melanoma, sarcoma, breast cancer, peritoneal malignancies, colorectal cancer.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 01 Jul 2021

Fausto Petrelli

Reviewer 1: Luca Campana

The authors of this systematic review and meta-analysis assessed the influence of oligometastatic disease status on OS and PFS in adult patients with solid tumours. To do this, they carried out an extensive literature review including all types of studies with at least ten patients with any histology. Patients with OM disease were found to have significantly longer PFS and OS if they had CRC, BC, NSCLC, RCC, and sarcoma.

The literature screening was conducted according to the standard recommendations and the subsequent analysis is methodologically robust. Going across several histotypes, the

paper provides a big, and for certain aspects, unique picture of the prognosis of patients with OM. At the same time, however, it makes it challenging summarising and discussing the results.

Here you can find some comments that you may find useful to improve this review:

- In the Abstract, I would mention the histotypes in which the OM status do not correlate with patient outcome. Also, in the Conclusions part, second sentence: this seems to be unrelated to the results presented and anyway not applicable in all cases (consider rephrasing/changing).
 - **Author response: OK - requests accepted.**
- The Introduction needs some input because sentences do not always follow a clear pattern. For instance, there are some general considerations regarding tumour progression, tumour staging according to the TNM, detailed results of a specific trial. It needs to be more homogeneous.
 - **Author response: OK - sentences added or modified.**
- Given the positive results with ablative therapies in patients with OM disease, the authors should explain what this meta-analysis adds to the literature.
 - **Author response: Sentences added in 2nd paragraph of discussion.**
- From the Introduction (and Methods) it is not clear what the definition adopted of OM disease is ("up to 3 to 5" metastatic sites). In this regard, is a patient with 6 liver metastases still considered "oligometastatic"?
 - **Author response: Definition updated.**
- The great majority of the studies were retrospective in nature. This should be clearly stated and critically discussed as well.
 - **Author response: Considerations added in the limitations section.**
- Did the authors detect any imbalance in treatment intensity between OM vs. non-OM patients?
 - **Author response: This data was not reported.**
- Table 1, 8th column: some of the included studies have "various" sites of OM. I think this information should be specified in order to be consistent with the inclusion criteria.
 - **Author response: "Various" means that in those articles, sites of metastases were not specific. Only when explicitly reported they are included (e.g liver or lung). Specific comment in inclusion criteria added.**
- The studies could be regrouped according to the histology. The same could apply to Figure 2 and Figure 3.
 - **Author response: Table and Figure 2 (OS) arranged according to disease.**
- The prognosis of patients with gastric cancer, melanoma, and head and neck cancer

should be discussed in light of the results presented.

- **Author response: Sentences added in the Discussion.**
- In the Discussion, it is not entirely clear if the authors consider the OM status an opportunity to spare patients from systemic treatment or an opportunity to pursue combined treatment. Again, this should be discussed in light of the results presented.
 - **Author response: In the final paragraph, some sentences were added about this request.**
- In the Discussion, the last paragraph seems more like a list of ongoing trials, including some form of local therapies over standard systemic treatment. How does this relate to the findings of the present study? Please discuss.
 - **Author response: Discussion added.**

Competing Interests: none

Author Response 02 Jul 2021

Fausto Petrelli

- We have improved the Introduction and criteria for search.
- We have arranged in the Discussion section a specific discussion about particular settings of patients analysed and the main limitation of the paper (retrospective nature of studies).
- We also discussed the main meaning of the results: improved prognosis and treatment opportunities with locoregional therapies in an oligometastatic setting.
- Table was also ordered according to histology.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research